Anchor Capital Advisors LLC Has $405,000 Stake in Pfizer Inc. (NYSE:PFE)

Anchor Capital Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,466 shares of the biopharmaceutical company’s stock after selling 840 shares during the period. Anchor Capital Advisors LLC’s holdings in Pfizer were worth $405,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in PFE. Kerusso Capital Management LLC acquired a new stake in Pfizer during the second quarter worth approximately $2,919,000. Acadian Asset Management LLC grew its position in shares of Pfizer by 3.6% during the 2nd quarter. Acadian Asset Management LLC now owns 326,990 shares of the biopharmaceutical company’s stock worth $9,144,000 after buying an additional 11,246 shares during the period. Asset Dedication LLC increased its stake in shares of Pfizer by 4.2% in the 2nd quarter. Asset Dedication LLC now owns 16,695 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 669 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at $38,000. Finally, Norden Group LLC boosted its stake in Pfizer by 52.7% during the second quarter. Norden Group LLC now owns 46,330 shares of the biopharmaceutical company’s stock worth $1,296,000 after acquiring an additional 15,994 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, August 19th. Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Performance

NYSE PFE opened at $28.56 on Monday. The company has a fifty day moving average price of $29.06 and a 200-day moving average price of $28.05. The firm has a market cap of $161.84 billion, a price-to-earnings ratio of -475.92, a PEG ratio of 1.00 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.